27.01.2010 • NewsJohnson Matthey

Johnson Matthey Sees Recovery in Key Markets

Johnson Matthey has reported that it had seen the beginnings of recovery in many of its key markets in the last three months of 2009. Sales for the fiscal third quarter excluding precious metals were 9% ahead of a year earlier and underlying pretax profit was up 20% as the company said it continued to benefit from reduced interest costs due to low borrowings and lower interest rates. The company said adjusted pretax profit for the full year is now expected to be slightly ahead of the current market consensus of $391 million.

Company

Johnson Matthey

Orchard Road
SG8 5HE Royston, Herts
UK

Company contact







Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.